📊 AKTX Key Takeaways
Is Akari Therapeutics Plc (AKTX) a Good Investment?
Akari Therapeutics is a pre-revenue pharmaceutical company experiencing severe financial distress with a critical liquidity crisis (current ratio 0.27x) and approximately 1.2 years of cash runway at current burn rates. The company posted -$14.5M net loss with -$2.5M operating cash burn, indicating ongoing operational non-viability without significant capital raises. While net losses improved 12.6% YoY, the fundamental financial position remains untenable for near-term survival.
Akari Therapeutics appears to be a pre-revenue biotech with no demonstrated commercial operating base, persistent operating and net losses, and negative free cash flow. The balance sheet is particularly weak from a liquidity standpoint, with just $2.48M of cash against a 0.19x current ratio, suggesting meaningful near-term financing risk despite no material long-term debt. Fundamentally, the company’s financial profile depends more on external capital access than on internally generated earnings or cash flow.
Akari Therapeutics Plc Key Strengths (AKTX)
- No long-term debt outstanding - not overleveraged or constrained by debt service
- Net loss improving year-over-year - demonstrates reduced cash burn trajectory
- Positive stockholders equity ($14.4M) - not technically insolvent yet
- No meaningful long-term debt reduces balance-sheet leverage risk
- Positive stockholders' equity of $22.69M provides some residual balance-sheet support
- Asset base of $45.38M may offer flexibility relative to liabilities
AKTX Stock Risks: Akari Therapeutics Plc Investment Risks
- Critical liquidity crisis - current ratio of 0.27x indicates current liabilities exceed current assets by 3.7x, severe working capital deficit
- Pre-revenue model - no commercial revenue generation, entirely dependent on external funding or asset sales
- Immediate cash runway risk - $2.8M cash with $2.5M annual burn rate provides approximately 13.4 months of operations before depletion
- Severely negative returns - ROE of -100.5% and ROA of -42.7% destroying shareholder value
- Dilution risk - company likely requires immediate equity raises to survive, causing shareholder dilution
- Severe liquidity pressure, with cash of $2.48M and a 0.19x current ratio
- No revenue and deeply negative operating income indicate an unproven business model
- Negative operating cash flow and free cash flow imply continued dependence on dilution or external financing
Key Metrics to Watch
- Cash balance and monthly burn rate - monitor for capital raise announcements or bankruptcy risk
- Revenue recognition or pipeline advancement announcements - any progress toward commercialization
- Changes to current ratio and working capital position - indication of solvency trajectory
- Cash runway relative to quarterly operating cash burn
- Any emergence of sustainable revenue or major improvement in operating loss
Akari Therapeutics Plc (AKTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
AKTX Profit Margin, ROE & Profitability Analysis
AKTX vs Healthcare Sector: How Akari Therapeutics Plc Compares
How Akari Therapeutics Plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Akari Therapeutics Plc Stock Overvalued? AKTX Valuation Analysis 2026
Based on fundamental analysis, Akari Therapeutics Plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Akari Therapeutics Plc Balance Sheet: AKTX Debt, Cash & Liquidity
AKTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Akari Therapeutics Plc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.
AKTX Revenue Growth, EPS Growth & YoY Performance
Akari Therapeutics Plc Dividends, Buybacks & Capital Allocation
AKTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Akari Therapeutics Plc (CIK: 0001541157)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AKTX
What is the AI rating for AKTX?
Akari Therapeutics Plc (AKTX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AKTX's key strengths?
Claude: No long-term debt outstanding - not overleveraged or constrained by debt service. Net loss improving year-over-year - demonstrates reduced cash burn trajectory. ChatGPT: No meaningful long-term debt reduces balance-sheet leverage risk. Positive stockholders' equity of $22.69M provides some residual balance-sheet support.
What are the risks of investing in AKTX?
Claude: Critical liquidity crisis - current ratio of 0.27x indicates current liabilities exceed current assets by 3.7x, severe working capital deficit. Pre-revenue model - no commercial revenue generation, entirely dependent on external funding or asset sales. ChatGPT: Severe liquidity pressure, with cash of $2.48M and a 0.19x current ratio. No revenue and deeply negative operating income indicate an unproven business model.
What is AKTX's revenue and growth?
Akari Therapeutics Plc reported revenue of N/A.
Does AKTX pay dividends?
Akari Therapeutics Plc does not currently pay dividends.
Where can I find AKTX SEC filings?
Official SEC filings for Akari Therapeutics Plc (CIK: 0001541157) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AKTX's EPS?
Akari Therapeutics Plc has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AKTX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Akari Therapeutics Plc has a D grade with 90% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AKTX stock overvalued or undervalued?
Valuation metrics for AKTX: ROE of -100.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AKTX's AI grade for 2026?
Our dual AI analysis gives Akari Therapeutics Plc a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AKTX's free cash flow?
Akari Therapeutics Plc's operating cash flow is $-2.5M, with capital expenditures of $42.1K.
How does AKTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -100.5% (avg: 15%), current ratio 0.27 (avg: 2).